Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-05-24
2010-11-23
Mondesi, Robert (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
Reexamination Certificate
active
07838016
ABSTRACT:
Metabolic auxotroph ofVibrio cholerae0139 synonym Bengal which has a mutation in its hem A gene and which is not capable of synthesizing aminolevulinic acid (ALA) de novo and which is obtained from a parent strain originally isolated from a patient's coproculture having all the identifying characteristics ofVibrio cholerae0139 synonym Bengal is described. In this strain the hem A gene is mutated by inserting a kanamycin resistant gene cassette. Another metabolic auxotroph ofVibrio cholerae01 E1 Tor where the hem A gene is mutated by a frame shift mutation is disclosed. Methods of producing the strains are disclosed.
REFERENCES:
Rijpkema et al.( Infection and Immunity vol. 60, No. 6,pp. 21-88-2193).
Result 2 AF227752 sequence alignment to SEQ ID No. 1.
Dalsgaard et al. ( Antimicrobial Agents and Chemotherapy, vol. 44, n.5, pp. 1315-1321, May 2000).
Rijpkema et al.( Infection and Immunity vol. 60, No. 6,pp. 2188-2193, Jun. 1992 ).
Result 2 AF227752 sequence alignment to SEQ ID No. I , Jan. 22, 2000.
Dalsgaard et al. ( Antimicrobial Agents and Chemotherapy, vol. 44, n.5, pp. 1315-1321, May 2000).
D.A. Sack et al., “Antibody Responses After Immunization With Killed Oral Cholera Vaccines During The 1985 Vaccine Field Trial in Bangladesh,” The Journal of Infectious Diseases, 1991, pp. 164:407-11.
Talena Ledon et al., “Construction and Characterisation of O139 Cholera Vaccine Candidates,” www.elsevier.com/locate/vaccine, 21 (2003), pp. 1282-1291.
R. Germanier et al., “Antigenicity of Cholorea Toxoid In Humans,” The Journal of Infectious Diseases, vol. 135, No. 4, Apr. 1977.
M. J. Angelichio et al., “Vibrio choleraeIntestinal Population Dynamics In The Suckling Mouse Model of Infection”, Infection and Immunity, Aug. 1999, vol. 67, p. 3733-3739.
S. R. Attridge et al., “Sensitive Microplate Assay for Detection of Bactericidal Antibodies toVibrio chloerae0139”, Clin. Diagn. Lab Immunol., vol. 9, pp. 383-387, Mar. 2002.
V. P. Bondre, et al., Evaluation of Different Subcellular Fractions ofVibrio cholerae0139 In Protection to Challenge In Experimental Cholera,FEMSImmunol. Med. Microbiol., vol. 19 (1998), pp. 323-329.
J. R. Butterton et al., “Heterologous Antigen Expression InVibrio choleraeVector Strains”, Infection and Immunity, Jul. 1995, vol. 63, pp. 2689-2696.
R. A. Cash et al., “Live Oral Cholera Vaccine: Evaluation of The Clinical Effectiveness of Two Strains In Humans”, Infection and Immunity, vol. 10, pp. 762-764, 1974.
J. D. Clemens et al., “B Subunit-Whole Cell and Whole Cell-Only Oral Vaccines Against Cholera: Studies on Reactogenicity and Immunogenicity,” The Journal of Infectious Diseases, vol. 155, Jan. 1987, pp. 79-85.
J. D. Clemens et al., “Field Trial of Oral Cholera Vaccines In Bangladesh:Results of One-Year Follow-Up,” The Journal of Infectious Diseases, vol. 158, No. 1, Jul. 1988.
S. N Cohen, et al., “Nonchromosomal Antibiotic Resistance In Bacteria: Genetic Transformation ofEscherichia coliBy R-Factor DNA”, Proc. Natl. Acad. Sci. vol. 69 (8): pp. 2110-2114, Aug. 1972.
Trinka S. Coster, et al., “Safety, Immunogencity, and Efficacy of Live AttenuatedVibrio cholerae0139 Vaccine Prototype,” vol. 345, Apr. 15, 1995.
Stephen Cooper, “Helical Growth and The Curved Shape ofVibrio colerae,”FEMS Microbiology Letters, 198 (2001), pp. 123-124.
S. M. Faruque et al., “Epidemiology, Genetics, an d Ecology of ToxigenicVibrio cholera”,Microbiology and Molecular Biology Reviews, Dec. 1998, vol. 62, No. 4, pp. 1301-1314.
R. Germanier et al., “Preparation of A Purified Antigenic Cholera Toxoid,” Infection and Immunity, Jun. 1976, vol. 13, No. 6, pp. 1692-1698.
Marianne Jertborn et al., Intestinal and Systemic Immune Responses In Humans After Oral Immunization With A Bivalent B Subunit-O1/O139 Whole Cell Cholera Vaccine, Vaccine, vol. 14, No. 15, pp. 1459-1465, 1998.
Thareerat Kalambaheti et al., “Immunogenicity and Protective Role of Three Formulations of Oral Cholera Vaccine,” Vaccine, vol. 16., No. 2/3, pp. 201-207, 1998.
Myron M. Levine, et al., “Evaluation In Humans of AttenuatedVibrio choleraeE1 Tor Ogawa Strain Texas Star-SR As A Live Oral Vacine,” Infection and Immunity, Feb. 1984, vol. 43, No. 2, pp. 515-522.
Frits R. Mooi et al., “The Evolution of EpidemicVibrio choleraStrains,” Trends In Microbiology, vol. 5, No. 4, Apr. 1997.
G. Balakrish Nair, et al., “New Bariants ofVibrio choleraO1 Biotype E1 Tor With Attributes of The Classical Biotype from Hospitlized Patients with Acute Diarrhea in Bangladesh,” Journal of Clinical Microbiology, Sep. 2002, vol. 40, No. 9, pp. 3296-3299.
Vida K. Parsi,M.D., “Cholera,” Elsevier Science Inc., 2001.
Nathaniel F. Pierce, et al., “Determinants of the Immunogenicity of Live Virulent and MutantVibrio choleraeO1 in Rabbit Intestine,” Infection and Immunity, Feb. 1987, vol. 55, No. 2, pp. 477-481.
Edward T. Ryan, et al., “Cholera Vaccines,” Clinical Infectious Diseases, 2000; vol. 31, pp. 561-565.
Joachim Reidl et al., “Vibrio choleraeand cholera: Out of The Water and Into The Host,” FEMS Microbiology Reviews, vol. 26 (2002), pp. 125-139.
William M. Spira, et al., “Simple Adult Rabbit Model forVibrio choleraand EnterotoxigenicEsherichia coliDiarrhea,” Infection and Immunity, May 1981, vol. 32, No. 2, pp. 739-747.
David N. Taylor et al., “Safety, Immunogenicity, And Lot Stability of The Whole Cell/Recombinant B Subunit (WC/rCTB) Cholera Vaccine In Peruvian Adults And Children,” Am. J. Trop. Med. Hyg., 1999, pp. 869-873..
M. Thungapathra et al., Construction of A Recombinant Live Oral Vaccine From A Non-toxigenic Strain ofVibrio choleraeO1 Serotype Inaba Biotype E1 Tor and Assessment of Its Reactogenicity and Immunogenicity In The Rabbit Model, Immunology Letters, vol. 68 (1999), pp. 219-227.
Edgar Valle, et al., “Construction and Characterization of A Nonproliferative E1 Tor Cholera Vaccine Candidate Derived From Strain 638,” American Society for Microbiology, 2000.
D. A. Sack et al., “Antibody Responses After Immunization With Killed Oral Cholera Vaccines During the 1985 Vaccine Field Trial In Bangladesh,” The Journal of Infectious Diseases, 1991, 164, pp. 407-411.
Edgar Valle, et al., “Construction and Characterization of A Nonproliferative E1 Tor Cholera Vaccine Candidate Derived From Strain 638,” Infection and Immunity, Nov. 2000, pp. 6411-6418.
Ali Syed Atif
Pattabiraman Lalitha
Rashid Nur Haslindawaty Abdul
Ravichandran Manickam
Zainuddin Zainul Fadziruddin
Lowe Hauptman & Ham & Berner, LLP
Mondesi Robert
Shahnan-Shah Khatol
Universiti Sains Malaysia
LandOfFree
Vibrio cholerae strains VCUSM1 and VCUSM4, method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vibrio cholerae strains VCUSM1 and VCUSM4, method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vibrio cholerae strains VCUSM1 and VCUSM4, method of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170246